ES2240526T3 - Composicion farmaceutica para inmunizar contra el sida. - Google Patents

Composicion farmaceutica para inmunizar contra el sida.

Info

Publication number
ES2240526T3
ES2240526T3 ES01976378T ES01976378T ES2240526T3 ES 2240526 T3 ES2240526 T3 ES 2240526T3 ES 01976378 T ES01976378 T ES 01976378T ES 01976378 T ES01976378 T ES 01976378T ES 2240526 T3 ES2240526 T3 ES 2240526T3
Authority
ES
Spain
Prior art keywords
mug
antigen
hiv
igg
dcchol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01976378T
Other languages
English (en)
Spanish (es)
Inventor
Jean Haensler
Francois Dalencon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Sanofi Vaccines US Inc
Original Assignee
Sanofi Pasteur SA
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur SA, Sanofi Pasteur Inc filed Critical Sanofi Pasteur SA
Application granted granted Critical
Publication of ES2240526T3 publication Critical patent/ES2240526T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Motorcycle And Bicycle Frame (AREA)
ES01976378T 2000-10-06 2001-10-08 Composicion farmaceutica para inmunizar contra el sida. Expired - Lifetime ES2240526T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0012808 2000-10-06
FR0012808A FR2814958B1 (fr) 2000-10-06 2000-10-06 Composition vaccinale

Publications (1)

Publication Number Publication Date
ES2240526T3 true ES2240526T3 (es) 2005-10-16

Family

ID=8855083

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01976378T Expired - Lifetime ES2240526T3 (es) 2000-10-06 2001-10-08 Composicion farmaceutica para inmunizar contra el sida.
ES01976380T Expired - Lifetime ES2275738T3 (es) 2000-10-06 2001-10-08 Composicion vacunal.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01976380T Expired - Lifetime ES2275738T3 (es) 2000-10-06 2001-10-08 Composicion vacunal.

Country Status (12)

Country Link
US (3) US20040038922A1 (de)
EP (2) EP1326635B1 (de)
AT (2) ATE350057T1 (de)
AU (2) AU2001295671A1 (de)
CA (1) CA2424836A1 (de)
CY (1) CY1105943T1 (de)
DE (2) DE60110822T2 (de)
DK (1) DK1326636T3 (de)
ES (2) ES2240526T3 (de)
FR (1) FR2814958B1 (de)
PT (2) PT1326636E (de)
WO (2) WO2002028427A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0855184A1 (de) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DK1077722T3 (da) 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
DE60044236D1 (de) 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
DE60039715D1 (de) * 1999-11-19 2008-09-11 Csl Ltd Hcv-impfstoff zusammensetzungen
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
US20080044435A1 (en) * 2004-03-16 2008-02-21 Cohen David I Tat-Based Tolerogen Compositions and Methods of Making and Using Same
EA007232B1 (ru) * 2001-08-17 2006-08-25 Коли Фармасьютикал Гмбх Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
NZ540098A (en) 2002-10-29 2008-09-26 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US7956043B2 (en) * 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
EP1608403A2 (de) * 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatorische nukleinsäure öl-in-wasser emulsionen zur topischen anwendung
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
JP4989225B2 (ja) * 2003-09-25 2012-08-01 コーリー ファーマシューティカル グループ，インコーポレイテッド 核酸親油性接合体
US20050208482A1 (en) * 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
JP2008506789A (ja) * 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
US20060165717A1 (en) * 2005-01-25 2006-07-27 Sanofi Pasteur DCchol in newborns
FR2881050B1 (fr) * 2005-01-25 2007-02-23 Sanofi Pasteur Sa Dcchol chez les nouveaux-nes
WO2007008463A2 (en) * 2005-07-07 2007-01-18 Coley Pharmaceutical Group, Inc. Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
JP5692933B2 (ja) 2009-03-23 2015-04-01 ナニアールエックス セラピューティックス インコーポレイテッド 免疫刺激ＨＩＶＴａｔ誘導体ポリペプチドによる腫瘍治療
WO2015051245A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
FR2732605B1 (fr) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
FR2732895B1 (fr) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
FR2781160B1 (fr) * 1998-07-03 2000-08-18 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
FR2783170B1 (fr) * 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
WO2000050006A2 (en) * 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
US20050249794A1 (en) * 1999-08-27 2005-11-10 Semple Sean C Compositions for stimulating cytokine secretion and inducing an immune response
AU780535B2 (en) * 1999-08-27 2005-03-24 Inex Pharmaceuticals Corp. Compositions for stimulating cytokine secretion and inducing an immune response
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1

Also Published As

Publication number Publication date
FR2814958B1 (fr) 2003-03-07
DK1326636T3 (da) 2007-04-30
CA2424836A1 (en) 2002-04-11
US20040038922A1 (en) 2004-02-26
AU2001295671A1 (en) 2002-04-15
EP1326635B1 (de) 2005-05-11
ES2275738T3 (es) 2007-06-16
DE60125797T2 (de) 2007-12-06
DE60110822D1 (de) 2005-06-16
WO2002028428A2 (fr) 2002-04-11
WO2002028427A2 (fr) 2002-04-11
FR2814958A1 (fr) 2002-04-12
EP1326635A2 (de) 2003-07-16
AU2001295673A1 (en) 2002-04-15
WO2002028427A3 (fr) 2003-03-20
CY1105943T1 (el) 2011-04-06
PT1326635E (pt) 2005-08-31
PT1326636E (pt) 2007-02-28
DE60125797D1 (de) 2007-02-15
US20030190326A1 (en) 2003-10-09
WO2002028428A3 (fr) 2003-02-20
US20050118188A1 (en) 2005-06-02
DE60110822T2 (de) 2006-05-11
EP1326636A2 (de) 2003-07-16
ATE295180T1 (de) 2005-05-15
ATE350057T1 (de) 2007-01-15
EP1326636B1 (de) 2007-01-03

Similar Documents

Publication Publication Date Title
US20050118188A1 (en) Pharmaceutical composition for immunization against AIDS
Okada et al. Intranasal immunization of a DNA vaccine with IL-12-and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens
ES2437585T3 (es) Vesículas de tipo virosoma que comprenden antígenos derivados de gp41
ES2242954T3 (es) Vacuna genetica para el virus de la inmunodeficiencia.
Sasaki et al. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1
ES2257072T3 (es) Composicion de vacuna antigripal.
JP4050310B2 (ja) Ｄｎａ転写ユニットの接種による免疫化
Manocha et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target
ES2416629T3 (es) Vacunas polivalentes de ADN de glicoproteína de VIH-1 primaria y procedimientos de vacunación
US8182821B2 (en) Flu vaccine admixture of mannan and flu antigen
US6749856B1 (en) Mucosal cytotoxic T lymphocyte responses
US8936789B2 (en) Immunoenhancer-linked oligomeric HIV envelope peptides
EP0722338B1 (de) Impfstoffe bestehend aus protein- oder peptid-"cochleaten" und deren verwendung zur immunisierung
ES2339762T3 (es) Vacuna contra el vih y procedimiento de uso.
ES2366185T3 (es) Vacunas de péptidos sintéticas para vih: el epítopo de cbd como un inmunógeno eficaz para provocar anticuerpos ampliamente neutralizantes contra el vih.
US20230149537A1 (en) Vaccines, adjuvants, and methods of generating an immune response
ES2236941T3 (es) Respuesta mucosal linfocitos t citotoxicos.
CN102365095B (zh) 分裂gp41
CN107208110A (zh) 用于诱导特异性抗体和细胞免疫的dna基序化合物和方法
US20120258124A1 (en) Antigen-antibody complexes as hiv-1 vaccines
EA021191B1 (ru) НОВЫЕ АНТИГЕНЫ gp41
AU2003293733B2 (en) Novel amine-based adjuvant
ES2345198T3 (es) Composicion y procedimientos inmunologicos.
EP0328390A2 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten
Berzofsky et al. Mucosal Vaccines to Induce Cellular Immunity Against HIV and Other Viral Infections